ArticleEuropean journal of medical research2025
FBXW7 regulates MAP7 through ubiquitination to affect the phenotypic characteristics and paclitaxel sensitivity of paclitaxel-resistant lung adenocarcinoma cells.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThe emergence of resistance to paclitaxel (PTX) poses a major challenge to the effective treatment of lung adenocarcinoma (LUAD). This study aimed to elucidate the role of microtubule-associated protein 7 (MAP7) in regulating cell phenotypes and PTX sensitivity of PTX-resistant LUAD cells.
methodsTwo PTX-resistant LUAD cell lines (A549/PTX and HCC-827/PTX) were generated. The effects on cell apoptosis, migration, invasiveness, tube formation, colony formation, and proliferation were evaluated. Subcutaneous xenograft studies were conducted to assess the in vivo role. The regulatory mechanism of F-Box and WD repeat domain containing 7 (FBXW7) on MAP7 protein was examined through stability analysis and immunoprecipitation (IP) assay.
resultsIn PTX-resistant LUAD tumors and cell lines, MAP7 expression was elevated (P < 0.001), while FBXW7 expression was reduced (P < 0.001). Depletion of MAP7 hindered the colony formation (P = 0.0001 or P = 0.0005), invasiveness (P = 0.0004 or P = 0.0005), and migratory capacity (P = 0.0004 or P = 0.001) of A549/PTX and HCC-827/PTX cells. Furthermore, MAP7 overexpression attenuated the anti-cancer effects of PTX in subcutaneous xenograft models (P = 0.0081 or P < 0.001). Mechanistically, FBXW7 destabilized MAP7 protein stability (P < 0.001) by promoting its polyubiquitination at K48. Knockdown of FBXW7 enhanced cell colony formation (P = 0.0029 or P = 0.0007), invasiveness (P = 0.0005 or P < 0.0001), and migration (P = 0.0002 or P < 0.0001) of A549/PTX and HCC-827/PTX cells. Re-expression of MAP7 counteracted (P < 0.01) the inhibitory effects of elevated FBXW7 expression on these cellular processes. In addition, the FBXW7-MAP7 cascade was shown to regulate tube formation in human umbilical vein endothelial cells (HUVECs) (P < 0.01).
conclusionsOur findings indicate that the FBXW7-MAP7 axis plays a critical role in regulating the malignant phenotypes and PTX sensitivity of PTX-resistant LUAD cell lines, suggesting a potential therapeutic strategy to improve the efficacy of PTX-based therapies in LUAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.